This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-20. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Genetics === Alport syndrome is caused by mutations in COL4A3, COL4A4, and COL4A5, three of six human genes involved in basement membrane (type IV) collagen biosynthesis. Mutations in any of these genes prevent the proper production or assembly of the specialised type IV collagen '345' network which is an important structural component of basement membranes in the kidney, inner ear, and eye. It is also found in other locations, including the alveoli of the lungs. Basement membranes are thin, sheet-like structures that separate and support cells in many tissues. Type IV collagen '112' type is found in both vertebrates and invertebrates and is the major isoform in most human basement membranes. When mutations prevent the formation of 345 type IV collagen network in the glomerulus, the 112 network, which is formed in fetal development but usually replaced by 345, persists into adult life.
When chondronectin is in the presence of guanidium chloride and cysteine, it has a subunit molecular weight of 55,540 +/- 800 Daltons. They have also been noted to be similar in structure and function to fibronectin proteins, but they interact with different types of proteins and molecules in the matrix. Chondronectin has a three-part shape. This keeps the protein steady while it interacts with many nearby molecules. Proteins that help link cells must remain strong in order to function properly. They need to stay connected without breaking apart. Strong chemical bonds help keep this structure together during physical stress. Chondronectin is found in joint fluid, eye fluid, and blood. These tissues need enough support and cushioning to function well. Because these areas are exposed to constant movement and fluid changes, the protein must remain strong and stable. It helps tissues stay connected even when fluid moves around them. Finding chondronectin in several places shows that it helps support multiple tissues rather than only one area.
In the extracellular space in tissues, type III collagen monomers assemble into macromolecular fibrils, which aggregate into fibers, providing a strong support structure for tissues requiring tensile strength. The triple-helical conformation, which is a characteristic feature of all fibrillar collagens, is possible because of the presence of glycine as every third amino acid in the sequence of about 1000 amino acids. When the right-handed super-helix is formed, the glycine residues of each of the monomers are positioned at the center of the super-helix (where the three monomers "touch"). Each left-handed helix is characterized by a complete turn in about 3.3 amino acids. The periodicity induced by the glycines at non-integer spacing results in a super-helix that completes one turn in about 20 amino acids. This (Gly-X-Y)n sequence is repeated 343 times in the type III collagen molecule. Proline or hydroxyproline is often found in the X- and Y-position giving the triple helix stability. Several fragments of human type III collagen have been solved by X-ray crystallography, including the C-terminal propeptide trimer that governs chain selection during procollagen assembly and a cystine-knot-containing triple-helical peptide near the C-terminus, which was found to adopt both 7/2 and 10/3 triple-helical symmetries. Full-length fibrillar collagen has not been crystallized because of its length and flexibility.
Collagen casings are mainly produced from the collagen in beef or pig hides, and the bones and tendons. It can also be derived from poultry and fish. They have been made for more than 50 years and their share of the market has been increasing. Usually the cost to produce sausages in collagen is significantly lower than making sausages in gut because of higher production speeds and lower labor requirements. The collagen for artificial casings is processed extensively. It is formed by extrusion through a die to the desired diameter, dried and shirred into short sticks up to 41 cm (16 in) long that contain as much as 50 m (160 ft) of casing. In a newer process, a form of dough is coextruded with the meat blend, and a coating is formed by treating the outside with a calcium solution to set the coating. The latest generation of collagen casings are usually more tender than natural casings and do not exhibit the "snap" or "bite" of natural casing sausages. Most collagen casings are edible, but a special form of thicker collagen casings is used for salamis and large caliber sausages where the casing is usually peeled off the sausage by the consumer. Collagen casings are less expensive to use, give better weight and size control, and are easier to run when compared to natural casings.
Sources: en.wikipedia.org
== Bibliography == Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Butterworth-Heinemann. doi:10.1016/C2009-0-30414-6. ISBN 978-0-08-037941-8. Penneman, R. A. and Keenan T. K. The radiochemistry of americium and curium, University of California, Los Alamos, California, 1960 Wiberg, Nils (2007). Lehrbuch Der Anorganischen Chemie. De Gruyter. ISBN 978-3-11-017770-1.
=== Social control and conformity === The concept of "mental illness" is often used to label and control those with beliefs and behaviours that the majority of people disagree with. The basic premise of the anti-psychiatry movement is that psychiatrists attempt to classify "normal" people as "deviant", psychiatric treatments are ultimately more damaging than helpful to patients; psychiatry's history involves discredited treatments, such as psychosurgery, an example of this being the frontal lobectomy (commonly called a lobotomy). The use of lobotomies largely disappeared by the late 1970s. On Michel Foucault's Madness and Civilization, Sapouna (2001) writes, "[his book provides] a framework to conceptualize confinement as a process of exclusion and 'silencing of the mad'."
===== Break ===== "The Bolivarian Republic of Venezuela has decided, in the full exercise of its sovereignty, to break diplomatic relations with the Republic of Paraguay and to proceed with the immediate withdrawal of its diplomatic personnel accredited in that country".- Statement by the Venezuelan executive (c. January 2025). Venezuela broke diplomatic relations with Paraguay on 6 January 2025 due to Santiago Peña's recognition of Edmundo González Urrutia as the winner of the election in Venezuela. Caracas considered this interference in its internal affairs and withdrew its diplomatic personnel from Asunción. In response, the Paraguayan government reaffirmed its support for González Urrutia and demanded the departure of the Venezuelan ambassador and his team within 48 hours.
Sources: en.wikipedia.org
By 1980, the BSAP comprised about 46,000 personnel; 11,000 professionals (about 60% black), and the remainder reservists (mostly white). The organisation's rank structure was unique, with different levels of seniority existing for black and white officers respectively. Until 1976, black officers could rise no further than sub-inspector, while the commissioned ranks were all-white. Limitations on black aspirations were removed in 1976. The first promotion of African members to previously European-only ranks occurred on 21 October 1976 with 23 Sub-Inspectors and 8 Detective Sub-Inspectors, a week later, being promoted to Patrol Officers.
Stark writes that the "characteristics of the earliest members of a movement will tend to be reproduced in subsequent converts." A significant percentage of Scientists remained single (Eddy placed little emphasis on marriage and family), or became Scientists when their children were adults and unlikely to be converted. Christian Science did not have missionaries, so it relied on internal growth, but the conversion rate within families was not high. In a study cited by Stark, of 80 people raised within Christian Science just 26 (33 percent) became Scientists themselves.
=== Wellman Plastics === All characters below appear in the first season and part of the second season before being written out altogether. Clooney would make one more appearance in a season four episode.
== Bibliography (in French) == Deligeorges, Stephane; Gady, Alexandre; Labalette, Françoise (2004). Le Jardin des Plantes et le Muséum national d'histoire naturelle (in French). Éditions du Patrimoine- Centre des Monuments Nationaux. ISBN 978-2-85822-601-6.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.